YS Biopharma (YSB) Short Interest Ratio & Short Volume

Short interest is the volume of YS Biopharma shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 38,900 shares of YSB short. 0.20% of YS Biopharma's shares are currently sold short. Learn More on YS Biopharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.20% of YS Biopharma's floating shares are currently sold short.

YS Biopharma saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 38,900 shares, a decline of 31.4% from the previous total of 56,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

YS Biopharma currently has issued a total of 93,058,000 shares. Some of YS Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. YS Biopharma currently has a public float of 19,640,000 shares.

0.20% of YS Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to YS Biopharma: ARS Pharmaceuticals, Inc. (25.60%), Gyre Therapeutics, Inc. (1.59%), Mesoblast Limited (1.22%), ANI Pharmaceuticals, Inc. (10.27%), Arcutis Biotherapeutics, Inc. (23.72%), Cassava Sciences, Inc. (38.60%), Calliditas Therapeutics AB (publ) (0.01%), Avadel Pharmaceuticals plc (9.82%), Cogent Biosciences, Inc. (7.70%), Bicycle Therapeutics plc (6.88%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling YSB is an investing strategy that aims to generate trading profit from YS Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for YS Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of YSB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including YSB, twice per month. The most recent reporting period available is May, 15 2024.